Primary Lateral Sclerosis Clinical Trial
Official title:
Screening and Natural History: Primary Lateral Sclerosis and Related Disorders
NCT number | NCT00015444 |
Other study ID # | 010145 |
Secondary ID | 01-N-0145 |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 1, 2001 |
Est. completion date | April 24, 2019 |
Verified date | April 24, 2019 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Objective:
The objectives of this protocol are:
to develop and maintain a repository of clinically characterized patients with primary
lateral sclerosis for future research protocols,
to characterize the natural history of neurodegenerative disorders with corticospinal neuron
degeneration,
to investigate proposed etiologies, risk factors, and biomarkers for the development of these
disorders and for disease progression
Study Population:
240 patients with adult-onset progressive spasticity with a diagnosis of primary lateral
sclerosis or related upper motor neuron disorder
Design:
Patients who have been referred by physicians for primary lateral sclerosis will undergo a
screening evaluation at the first visit. The screening visit will include review of outside
medical records, neurological examination, and diagnostic testing to determine possible
causes of spasticity. Patients fulfilling the clinical criteria for primary lateral sclerosis
by history or examination will be followed to determine the natural history of this disorder.
Measures of motor and cognitive function will be made at baseline and follow-up visits to
follow clinical progression. Magnetic resonance imaging will be carried out to determine if
imaging changes occur over time. Patients identified in this protocol who are eligible for
other research protocols will be invited to participate in additional protocols.
Outcome Measures:
Clinical progression will be documented by measures of finger-tapping, timed gait, speech.
The association between clinical progression and MRI measures will be assessed as a secondary
outcome....
Status | Completed |
Enrollment | 189 |
Est. completion date | April 24, 2019 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
- INCLUSION CRITERIA: - Age 18 years of age or older - Adult onset of progressive spasticity - No family history of a similar disorder - Able to provide consent or with a legally-authorized representative who can provide consent EXCLUSION CRITERIA: - History of stroke, cerebral palsy, traumatic brain injury or other known etiology of spasticity - Non-neurological disorders producing muscle stiffness, such as fasciitis or rheumatological conditions - Disorders in which pain limits the ability to move muscles, such as fibromyalgia or complex regional pain syndromes - Profound weakness of voluntary movement - Inability to travel to NIH - Anticoagulation will be an exclusion for needle EMG studies - Implanted devices or metal fragments in the brain or spinal cord will be an exclusion for MRI scanning |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Neurological Disorders and Stroke (NINDS) |
United States,
Auger RG. AAEM minimonograph #44: diseases associated with excess motor unit activity. Muscle Nerve. 1994 Nov;17(11):1250-63. Review. — View Citation
Bentley S. Exercise-induced muscle cramp. Proposed mechanisms and management. Sports Med. 1996 Jun;21(6):409-20. Review. — View Citation
Leclerc KM, Landry FJ. Benign nocturnal leg cramps. Current controversies over use of quinine. Postgrad Med. 1996 Feb;99(2):177-8, 181-4. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary outcome of this protocol is to document the natural history of clinical progression in PLS, defined as the change in clinical measures of movement speed over time: finger tapping, timed gait, and time to read a standard passage. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03067857 -
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02567136 -
Imaging Biomarkers in ALS
|
||
Recruiting |
NCT05204017 -
Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS
|
||
Completed |
NCT00324454 -
Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease
|
Phase 2 | |
Completed |
NCT01143428 -
Oxidative Stress in Motor Neuron Disease: COSMOS Add-On Study
|
||
Recruiting |
NCT06320444 -
Non-invasive Spinal, Cortical, and Sensorimotor Biomarkers in Motor Neurone Disease
|
||
Not yet recruiting |
NCT06315673 -
Digital Assessment of Speech and Fine Motor Control in ALS
|
||
Completed |
NCT03560661 -
Acoustic and Perceptual Markers of Dysarthria in Amyotrophic Lateral Sclerosis (ALS)
|
||
Recruiting |
NCT04875416 -
Phenotype, Genotype and Biomarkers 2
|
||
Active, not recruiting |
NCT03912987 -
TRIAL READY (Clinical Trial Readiness)
|
||
Withdrawn |
NCT05830214 -
Digital Smartwatch Measurements as Potential Biomarkers for Remote Disease Tracking in ALS
|
||
Recruiting |
NCT03489278 -
Clinical Procedures to Support Research in ALS
|
||
Completed |
NCT02852278 -
A Patient Centric Motor Neuron Disease Activities of Daily Living Scale
|
||
Completed |
NCT02574390 -
Answer ALS: Individualized Initiative for ALS Discovery
|
||
Recruiting |
NCT06012110 -
Transcutaneous Electrical Stimulation for Spasticity in Patients With Primary Lateral Sclerosis
|
N/A | |
Completed |
NCT00023075 -
Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis
|
N/A | |
Enrolling by invitation |
NCT02327845 -
Phenotype, Genotype & Biomarkers in ALS and Related Disorders
|
||
Completed |
NCT00677768 -
Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)
|
N/A |